“COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND” (2025) Proceedings of the International Conference on Public Health, 9(1), pp. 45–67. doi:10.17501/24246735.2024.9105.